These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 7160397)

  • 21. Prenalterol in severe congestive heart failure. II. Long-term oral treatment. Results with comments on the methods for evaluation of drugs in congestive heart failure.
    Tangø M; Lyngborg K; Jespersen C; Rehling M; Trap-Jensen J
    Dan Med Bull; 1988 Feb; 35(1):78-80. PubMed ID: 3342647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beta-adrenergic stimulation of the failing ventricle: a double-blind, randomized trial of sustained oral therapy with prenalterol.
    Roubin GS; Choong CY; Devenish-Meares S; Sadick NN; Fletcher PJ; Kelly DT; Harris PJ
    Circulation; 1984 May; 69(5):955-62. PubMed ID: 6142775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Haemodynamic and cardiac metabolic effects of the new beta 1 agonist prenalterol in patients with cardiac failure.
    Kupper W; Schütt M; Hamm CW; Kuck KH; Hanrath P; Bleifeld W
    Eur Heart J; 1983 Aug; 4(8):573-83. PubMed ID: 6139281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of prenalterol on cardiac performance and transmural myocardial perfusion in patients with chronic renal failure.
    Pedersen T; Cleemann-Rasmussen K; Brynjolf I; Ording H; Nielsen PE; Rasmussen K
    Eur J Clin Pharmacol; 1983; 25(3):287-92. PubMed ID: 6628515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Circulatory effects of prenalterol (selective beta-1 agonist) in normal subjects and in patients with primary congestive cardiomyopathy].
    Moruzzi P; Cipolla CM; Bartorelli A; Reggiani P; Lu Quo Ging ; Guazzi M
    Cardiologia; 1982; 27(1):99-101. PubMed ID: 6892381
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of i.v. prenalterol in patients with severe cardiac failure at rest and during exercise.
    Doering W; Wauer B; Isbary J
    Acta Med Scand Suppl; 1982; 659():307-14. PubMed ID: 6127897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prenalterol, an oral beta-1 adrenoceptor agonist, in the treatment of chronic heart failure.
    Sharpe DN; Coxon R
    Eur J Clin Pharmacol; 1983; 25(4):539-45. PubMed ID: 6653650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Haemodynamic effects of intravenously administered prenalterol in patients with severe heart failure.
    Waagstein F; Estrada-Yamamoto M; Reiz S; Reyes C; Hjalmarson A
    Acta Med Scand Suppl; 1982; 659():221-31. PubMed ID: 6127891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro studies on the cardiac activity of prenalterol with reference to use in congestive heart failure.
    Kenakin TP; Beek D
    J Pharmacol Exp Ther; 1982 Jan; 220(1):77-85. PubMed ID: 6118432
    [No Abstract]   [Full Text] [Related]  

  • 30. Prenalterol as long-term therapy for chronic congestive heart failure. A randomized cross-over trial.
    Dahlström U; Areskog M; Wranne B; Karlsson E
    Acta Med Scand; 1984; 216(2):199-207. PubMed ID: 6149671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hemodynamic effects of intravenous prenalterol in severe heart failure.
    Kirlin PC; Pitt B
    Am J Cardiol; 1981 Mar; 47(3):670-5. PubMed ID: 7468501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of prenalterol in healthy subjects and patients with congestive heart failure.
    Rönn O
    Acta Med Scand Suppl; 1982; 659():89-98. PubMed ID: 6127901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Use of prenalterol in cardiogenic shock occurring in acute myocardial infarct].
    Coma-Canella I
    Ter Arkh; 1982; 54(11):104-5. PubMed ID: 6130619
    [No Abstract]   [Full Text] [Related]  

  • 34. Hemodynamic and myocardial metabolic effects of the beta-agonist prenalterol in ischemic left ventricular dysfunction.
    Kirlin PC; Walton JA; Brymer JF; Beauman G; Pitt B
    J Cardiovasc Pharmacol; 1984; 6(5):852-8. PubMed ID: 6209491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Acute and chronic effects of oral cardiotonic agent, denopamine (TA-064) in patients with heart failure].
    Inden M; Yamamuro M; Murayama S; Noda E; Tanimura H; Takasaki H; Konishi T; Nakano T; Takezawa H
    Kokyu To Junkan; 1986 May; 34(5):541-6. PubMed ID: 3738247
    [No Abstract]   [Full Text] [Related]  

  • 36. [Hemodynamic studies on the effects of peruvoside on congestive heart failure].
    Gu F; Zhou W
    Zhonghua Xin Xue Guan Bing Za Zhi; 1992 Jun; 20(3):157-9. PubMed ID: 1289025
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacokinetics and plasma-concentration-effect relationships of prenalterol in cardiac failure.
    Sainsbury EJ; Fitzpatrick D; Ikram H; Nicholls MG; Espiner EA; Ashley JJ
    Eur J Clin Pharmacol; 1985; 28(4):397-403. PubMed ID: 2863151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Haemodynamic effects of prenalterol in patients on dialysis.
    Lustenberger N
    Acta Med Scand Suppl; 1982; 659():157-67. PubMed ID: 6127886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hemodynamic actions of prenalterol in severe congestive heart failure due to chronic coronary disease.
    Awan NA; Needham KE; Evenson MK; Win A; Mason DT
    Am Heart J; 1981 Feb; 101(2):158-61. PubMed ID: 7468416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prenalterol--a new cardioselective inotropic agent.
    Kendall MJ; Goodfellow RM; Westerling S
    J Clin Hosp Pharm; 1982 Jun; 7(2):107-18. PubMed ID: 7050180
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.